Lantheus (NASDAQ:LNTH) Price Target Raised to $125.00 at Truist Financial

Lantheus (NASDAQ:LNTH) had its price target raised by Truist Financial from $115.00 to $125.00 in a research report report published on Thursday, Marketbeat.com reports. The firm currently has a buy rating on the medical equipment provider’s stock.

A number of other equities research analysts also recently weighed in on LNTH. Wall Street Zen downgraded Lantheus from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Citizens Jmp reiterated a “market outperform” rating and issued a $115.00 target price on shares of Lantheus in a report on Monday, June 29th. B. Riley Financial increased their price target on shares of Lantheus from $97.00 to $129.00 and gave the company a “buy” rating in a research report on Thursday, July 9th. The Goldman Sachs Group restated a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a report on Thursday, May 7th. Finally, Mizuho lifted their price objective on shares of Lantheus from $115.00 to $120.00 and gave the stock a “market outperform” rating in a research report on Wednesday. Eight investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $110.43.

Lantheus Stock Up 0.8%

Lantheus stock opened at $105.11 on Thursday. The business has a fifty day moving average of $102.11 and a two-hundred day moving average of $84.07. The company has a quick ratio of 2.64, a current ratio of 2.83 and a debt-to-equity ratio of 0.47. The firm has a market cap of $6.84 billion, a P/E ratio of 25.33 and a beta of -0.06. Lantheus has a twelve month low of $47.25 and a twelve month high of $111.86.

Lantheus (NASDAQ:LNTH) last announced its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.25 by $0.21. The business had revenue of $377.33 million for the quarter, compared to analysts’ expectations of $354.48 million. Lantheus had a return on equity of 29.32% and a net margin of 18.05%.The business’s revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter last year, the firm earned $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, analysts forecast that Lantheus will post 4.5 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Western Wealth Management LLC purchased a new stake in Lantheus in the first quarter valued at about $25,000. Smartleaf Asset Management LLC grew its stake in shares of Lantheus by 63.3% during the fourth quarter. Smartleaf Asset Management LLC now owns 508 shares of the medical equipment provider’s stock worth $34,000 after acquiring an additional 197 shares during the last quarter. Parallel Advisors LLC increased its holdings in shares of Lantheus by 122.6% during the fourth quarter. Parallel Advisors LLC now owns 541 shares of the medical equipment provider’s stock valued at $36,000 after acquiring an additional 298 shares in the last quarter. Osterweis Capital Management Inc. acquired a new position in shares of Lantheus during the second quarter valued at about $36,000. Finally, Bessemer Group Inc. raised its position in shares of Lantheus by 221.2% in the 1st quarter. Bessemer Group Inc. now owns 514 shares of the medical equipment provider’s stock valued at $39,000 after purchasing an additional 354 shares during the last quarter. 99.06% of the stock is currently owned by hedge funds and other institutional investors.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.